新藥簡介：Nexavar、Eraxis、Aloxi - tma.tw

1 382009, , 39 23 2007 10 2008 1 nexavar eraxis aloxi N e x a v a r s o r a f e n i b i n t e r f e r o n - a l p h a interleukin-2 N e x a v a r ( m u l t i k i n a s e inhibitor) ( CRAF, BRAF, mutant BRAF) (KIT, FLT-3, VEGFR-2, VEGFR-3, PDGFR- ) Sutent (1) S u t e n t nexavar Neavar ( nexavar 400 mg) (overall survival, OS) (progression-free survival, PFS) (tumor response) nexavar n=384 PFS n=385 nexavar hazard ratio (95%CI: , , p< ) OS nexavar hazard ratio (95%CI.)

2 , , p = )(2) nexavar D nexavar ( ) Common Terminology Criteria for Adverse Events nexavar nexavar nexavar nexavar nexavar 400 mg anidulafungin E r a x i s (Aspergillus nidulans) echinocandin 1,3- -D-glucan eraxis / E r a x i s ( 200 mg 100 mg ) fluconazole ( 800 mg 400 mg ) 14 42 ( ) ( ) eraxis (n=127) fluconazole (n=118) (95%CI.

3 , 27)(3) eraxis fluconazole 2-3% nexavar eraxis aloxi / 202 392009, , eraxis eraxis 200 mg 100 mg 14 (palonosetron HCl) aloxi 5-HT3 aloxi 5-HT3 A l o x i 1 2 0-24 24-120 11 3 2 30 aloxi ( mg mg)

4 Ondansetron 32 mg dolasetron 100 mg aloxi mg ondansetron (p = ) (p < ) (4) aloxi mg dolasetron (p = ) (p = ) (5) 667 30 aloxi ( mg ) ondansetron 32 mg aloxi mg ondansetron (p = )(6) 5-HT3 aloxi QT prolongation QT syndrome QT prolongation aloxi 30 mg 30 1 carboplatin, epirubicin, idarubicin, ifosfamide, irinotecan or mitoxantrone; methotrexate >250 mg/m2; cyclophosphamide 1500 mg/m2; doxorubicin >25 mg/m2; cisplatin 50 mg/m2 2 cisplatin 60 mg/m2, cyclophosphamide >1500 mg/m2, carmustine >250 mg/m2, dacarbazine, mechlorethamine 1.

5 Sutent, Exjade, NuvaRing 2007;50:25-26 2. Escudier B, Eisen T, Stadler WM , et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356 Reboli AC, Rotstein C, Pappas PG, et al.: Anidulafungin 203 402009, , fluconazole for invasive candidiasis. N Engl J Med 2007;356 Gralla R, Lichinitser M, Van Der Vegt S, et al.: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.

6 Ann Oncol 2003;14 Eisenberg P, Figueroa-Vadillo J, Zamora R, et al.: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer 2003;98 Aapro MS, Grunberg SM, Manikhas GM, et al.: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17